Citigroup
SRNE

Citigroup’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Citigroup’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,000
Closed -$130K – 7698
2020
Q4 		$130K Sell
19,000
-5,100
-21% -$41K ﹤0.01% 5328
2020
Q3 		$269K Buy
24,100
+23,600
+4,720% +$216K ﹤0.01% 4380
2020
Q2 		$3K Buy
+500
New +$1.91K ﹤0.01% 7374

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Citigroup's SRNE Position: Q1 2023 in Review

Citigroup sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 1,922,143 shares — an estimated $1.7M sold.

Citigroup first reported a position in SRNE in Q2 2014 and held it in 35 quarters. The position peaked at $5.52M in Q2 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Citigroup reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 1,922,143 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $1.7M.
  • Citigroup first reported a position in Sorrento Therapeutics, Inc. in Q2 2014 and held it in 35 quarters.
  • Citigroup's Sorrento Therapeutics, Inc. position peaked at $5.52M in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.